Results from randomised human clinical trials look promising and indicate that administration of IL-1β antagonists in the first 72 h post-stroke dampens circulating pro-inflammatory cytokine levels in both blood and cerebrospinal fluid—whether this will translate into beneficial therapeutic outcomes has yet to be confirmed [115,116]. Here, IL1B is linked to stroke disorder.